Efficacy Study of Cognitive Intervention in Amnestic Mild Cognitive Impairment

NCT ID: NCT01358955

Last Updated: 2013-08-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

293 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-03-31

Study Completion Date

2013-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

* There will be a significant difference in cognitive function between cognitive intervention group (group therapy) and a wait list control group.
* There will be a significant difference in cognitive function between a home-based cognitive intervention group and a wait list control group.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The change of Modified ADAS-cog score from the baseline to post-intervention will be compared between the cognitive intervention group and wait list control group.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mild Cognitive Impairment

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

mild cognitive impairment cognitive therapy prevention

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group cognitive intervention

The cognitive training will be administered twice a week for 12 weeks, located in hospital-based outpatient memory clinics. Each session will last approximately 90 minutes. The cognitive training programs will be offered in group sessions consisted of 5 participants.

Group Type ACTIVE_COMPARATOR

group cognitive intervention

Intervention Type OTHER

The cognitive training will be administered twice a week for 12 weeks, located in hospital-based outpatient memory clinics. Each session will last approximately 90 minutes. The cognitive training programs will be offered in group sessions consisted of 5 participants.

Home-based cognitive intervention

The participants will do their homework for 30 minutes every business days for 12 weeks.

Group Type ACTIVE_COMPARATOR

Home-based cognitive intervention

Intervention Type OTHER

The participants will do their paper and pencil homework for 30 minutes every business days for 12 weeks.

Wait list Control

They will participate in cognitive intervention after ending this study.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

group cognitive intervention

The cognitive training will be administered twice a week for 12 weeks, located in hospital-based outpatient memory clinics. Each session will last approximately 90 minutes. The cognitive training programs will be offered in group sessions consisted of 5 participants.

Intervention Type OTHER

Home-based cognitive intervention

The participants will do their paper and pencil homework for 30 minutes every business days for 12 weeks.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 50 to 85 years of age
* memory complaint corroborated by a participant and an informant
* delayed recall score on the Seoul Verbal Learning Test (SVLT) below 1.0 standard deviations from the mean of the age and education-normative values among the Korean population
* Global CDR score is 0.5, Memory CDR score is 0.5 or 1.
* above 1.5 standard deviations from the mean of normative data of the respective age- and education-matched population on the Korean Mini-Mental State Examination
* normal functional activities
* not diagnosed with dementia
* Modified Hachinski Ischemic Score (HIS): 0-4
* brain magnetic resonance imaging or CT showing no clinical evidence of other diseases (i.e., normal pressure hydrocephalus, brain tumor, cerebrovascular disease) capable of producing cognitive impairment.
* Subjects are also required to have a reliable caregiver who meet the patient at least once a week and is sufficiently familiar with the patient to provide the investigator with accurate information.
* He/She can read and write
* written informed consent

Exclusion Criteria

* any patient who were involved in other clinical trials or treated with experimental drug within 4 weeks
* any patients with any severe or unstable medical disease that may prevent the patient from completing all study requirements (i.e., unstable or severe asthma or cardiovascular disease, active gastric ulcer, severe hepatic or renal disease)
* any patients with clinically significant laboratory abnormalities such as an abnormal thyroid function test, abnormal low level of vitamin B12 or folate, or positive venereal disease research laboratory test
* any patients with any primary neurodegenerative disorder or psychiatric disorder other than AD (i.e., Parkinson's disease, schizophrenia, or major depressive disorder)
* any patients with any history of drug or alcohol addiction during the past 10 years
* any hearing or visual impairment that can disturb the efficient evaluation of the patient
Minimum Eligible Age

50 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Eisai Inc.

INDUSTRY

Sponsor Role collaborator

Inha University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Chul Soo Kim

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Seong H Choi, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Inha University Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Korea University Medical College

Ansan, , South Korea

Site Status

Soonchunhyang University Hospital

Bucheon-si, , South Korea

Site Status

Bucheon St. Mary's Hospital, the Catholic University of Korea

Bucheon-si, , South Korea

Site Status

Donga University Hospital

Busan, , South Korea

Site Status

Pusan National University Hospital

Busan, , South Korea

Site Status

Daejun Eulji University Hopistal

Daejun, , South Korea

Site Status

Myongji Hospital

Goyang, , South Korea

Site Status

NHIC Ilsan Hospital

Goyang, , South Korea

Site Status

Inha Univeristy Hospital

Incheon, , South Korea

Site Status

Jeju National University Hospital

Jeju City, , South Korea

Site Status

Maryknoll Hospital

Pusan, , South Korea

Site Status

Bobath Memorial Hospital

Seongnam, , South Korea

Site Status

Sungkyunkwan University, Samsung Seoul Hospital

Seoul, , South Korea

Site Status

Asan Medical Center, Psychiatry

Seoul, , South Korea

Site Status

Inje University Sanggye Paik Hospital

Seoul, , South Korea

Site Status

Konkuk University Medical Cener

Seoul, , South Korea

Site Status

Ajou University Hospital

Suwon, , South Korea

Site Status

Hyoja Geriatric Hospital

Yŏngin, , South Korea

Site Status

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CogMCI study

Identifier Type: -

Identifier Source: org_study_id